NCT04246502
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with a history of anti-cancer therapy for metastatic breast cancer (MBC) with the exception of one prior hormonal regimen for MBC; Patients with a history of HER2 targeting tyrosine kinase inhibitors (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib) or monoclonal antibody for breast cancer in any treatment setting, except Herceptin/trastuzumab
https://ClinicalTrials.gov/show/NCT04246502